Loading stock data…
DARE
$2.34+0.06 (+2.63%)
Market ClosedLast close May 1
Daré Bioscience, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Daré Bioscience, Inc. in the Healthcare sector is trading at $2.34. The stock is currently near its 52-week low of $1.27, remaining 18.2% above its 200-day moving average. Technical signals show neutral RSI of 61 and bearish MACD signal, explaining why DARE maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.34
Potential Upside
5%
Whystock Fair Value$2.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the tre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$33.05M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.90
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-471.37%
Volume
Today's trading volume
342,505
Recent News
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates
Dare Bioscience (DARE) delivered earnings and revenue surprises of +91.67% and -28.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -45.28% and -45.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates
uniQure (QURE) delivered earnings and revenue surprises of +39.91% and -21.20%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ...
Dare Bioscience Inc (DARE) outlines its innovative pipeline progress and financial fortification, while navigating regulatory hurdles and market expansion plans.